Evaluation of antimicrobial susceptibility and integron carriage in Helicobacter pylori isolates from patients
Gastroenterology and Hepatology from Bed to Bench,
Vol. 9 No. Supplement 1 (2016),
8 December 2016
https://doi.org/10.22037/ghfbb.v0i0.981
Abstract
Aim: The purpose of this study was to determine the antibiotic susceptibility pattern and distribution of integron in H. pylori isolates collected from patients referred to private health care centers in Tehran, Iran.
Background: Antibiotic resistance is the main reason for failure of Helicobacter pylori therapy. Integrons as genetic reservoirs play main roles in the dissemination of antimicrobial resistance gene.
Methods: During a 12-month cross-sectional study period, 65 H. pylori isolates were recovered from 124 biopsy specimens. Isolates were subjected to susceptibility testing using by Epsilometer test according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guideline. PCR was used to detect different types of integrons.
Results: Antimicrobial susceptibility testing revealed that 73.8% of isolates were resistant to metronidazole, 43.1% to clarithromycin, 29.2% to tetracycline, 27.7% to amoxicillin, 23.1% to rifampicin and 13.4% to levofloxacin. Frequency of multidrug resistance among
H. pylori isolates was 26.1%. The most predominant resistance profiles among our isolates were included resistance to clarithromycin and metronidazole (20%). Class 1 and 2 integrons were detected in 8 (12.3%) and 15 (23.1%) of the isolates, respectively. Conclusions: The high prevalence of multidrug resistance and frequency of class 2 integron in this survey can be a warning for clinicians. Continuous surveillance is necessary for the development of new treatment protocols to prevent the treatment failures and also further spread of resistant isolates.
- H. pylori
- integron
- Multidrug-Resistant
How to Cite
References
Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection—the Maastricht IV/Florence consensus report. Gut 2012; 61: 646-64.
Eslami G, Taheri S, Baseri N, Montazeri SA, Shakeri A, Samadi R, et al. Prevalence of Helicobacter pylori and Determination of Antibiotic Resistance in Patients with Gastritis Referred to Shahid Beheshti University of Medical Sciences Hospitals in Tehran Between 2010 and 2011. Arch Clin Infect Dis 2012; 8: 18-22.
Thung I, Aramin H, Vavinskaya V, Gupta S, Park J, Crowe S, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 2016; 43: 514-33.
Feng L, Wen M-Y, Zhu Y-J, Men R-T, Yang L. Sequential therapy or standard triple therapy for Helicobacter pylori infection: an updated systematic review. Am J Ther 2016; 23: e880-e93.
Shokrzadeh L, Jafari F, Dabiri H, Baghaei K, Zojaji H, Alizadeh AH, et al. Antibiotic susceptibility profile of Helicobacter pylori isolated from the dyspepsia patients in Tehran, Iran. Saudi J Gastroenterol 2011; 17: 261-4.
Nishizawa T, Suzuki H. Mechanisms of Helicobacter pylori antibiotic resistance and molecular testing. Front Mol Biosci 2014; 1: 19.
Crespo O, Catalano M, Piñeiro S, Matteo M, Leanza A, Centrón D. Tn7 distribution in Helicobacter pylori: a selective paradox. Int J Antimicrob Agents 2005; 25: 341-4.
Kwon DH, Dore M, Kim J, Kato M, Lee M, Wu J, et al. High-level β-lactam resistance associated with acquired multidrug resistance in Helicobacter pylori. Antimicrob Agents Chemother 2003; 47: 2169-78.
Gillings MR. Integrons: past, present, and future. Microbiol Mol Biol Rev 2014; 78: 257-77.
Deng Y, Bao X, Ji L, Chen L, Liu J, Miao J, et al. Resistance integrons: class 1, 2 and 3 integrons. Ann Clin Microbiol Antimicrob 2015; 14: 45.
Moura A, Henriques I, Ribeiro R, Correia A. Prevalence and characterization of integrons from bacteria isolated from a slaughterhouse wastewater treatment plant. J Antimicrob Chemother 2007; 60: 1243-50.
Boyanova L, Evstatiev I, Gergova G, Yaneva P, Mitov I. Linezolid susceptibility in Helicobacter pylori, including strains with multidrug resistance. Int J Antimicrob Agents 2015; 46: 703-6.
Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-53.
Goudarzi H, Seyedjavadi SS, Fazeli M, Azad M, Goudarzi M. Genotyping of Peroxisome Proliferator-Activated Receptor gamma in Iranian Patients with Helicobacter pylori Infection. Asian Pac J Cancer Prev 2015; 16: 5219-23.
Milani M, Ghotaslou R, Akhi MT, Nahaei MR, Hasani A, Somi MH, et al. The status of antimicrobial resistance of Helicobacter pylori in Eastern Azerbaijan, Iran: comparative study according to demographics. J Infect Chemother 2012; 18: 848-52.
Álvarez A, Moncayo JI, Santacruz JJ, Santacoloma M, Corredor LF, Reinosa E. Antimicrobial susceptibility and mutations involved in clarithromycin resistance in Helicobacter pylori isolates from patients in the western central region of Colombia. Antimicrob Agents Chemother 2009; 53: 4022-4.
Torres J, Camorlinga-Ponce M, Pérez-Pérez G, Madrazo-De la Garza A, Dehesa M, González-Valencia G, et al. Increasing Multidrug Resistance inHelicobacter pylori Strains Isolated from Children and Adults in Mexico. J Clin Microbiol 2001; 39: 2677-80.
Gehlot V, Mahant S, Mukhopadhyay AK, Das K, De R, Kar P, et al. Antimicrobial susceptibility profiles of Helicobacter pylori isolated from patients in North India. J Glob Antimicrob Resist 2016; 5:51-6.
Wheeldon TU, Granström M, Hoang T, Phuncarg D, Nilsson L, Sörberg M. The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication. Aliment Pharmacol Ther 2004; 19: 1315-21.
Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013; 62: 34-42.
Chisholm S, Teare E, Davies K, Owen R. Surveillance of primary antibiotic resistance of Helicobacter pylori at centres in England and Wales over a six-year period (2000-2005). Euro Surveill 2007; 12: E3-4.
Ling T, Leung W, Lee C, Ng E, Yung M, Chung S, et al. The antimicrobial susceptibility of Helicobacter pylori in Hong Kong (1997–2001). Helicobacter 2002; 7: 327-8.
Manfredi M, Gismondi P, Maffini V, Bizzarri B, Fornaroli F, Madia C, et al. Primary Antimicrobial Susceptibility Changes in Children with Helicobacter pylori Infection over 13 Years in Northern Italy. Gastroenterol Res Pract 2015; 2015.
O'connor A, Taneike I, Nami A, Fitzgerald N, Murphy P, Ryan B, et al. Helicobacter pylori resistance to metronidazole and clarithromycin in Ireland. Eur J Gastroenterol Hepatol 2010; 22: 1123-7.
Asaka M, Kato M, Takahashi Si, Fukuda Y, Sugiyama T, Ota H, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010; 15: 1-20.
Ogata SK, Gales AC, Kawakami E. Antimicrobial susceptibility testing for Helicobacter pylori isolates from Brazilian children and adolescents: comparing agar dilution, E-test, and disk diffusion. Braz J Microbiol 2014; 45: 1439-48.
Chung JW, Lee GH, Jeong JY, Lee SM, Jung JH, Choi KD, et al. Resistance of Helicobacter pylori strains to antibiotics in Korea with a focus on fluoroquinolone resistance. J Gastroenterol Hepatol 2012; 27: 493-7.
Caliskan R, Tokman HB, Erzin Y, Saribas S, Yuksel P, Bolek BK, et al. Antimicrobial resistance of Helicobacter pylori strains to five antibiotics, including levofloxacin, in Northwestern Turkey. Rev Soc Bras Med Trop 2015; 48: 278-84.
Aboderin OA, Abdu A, Odetoyin BW, Okeke IN, Lawa OO, Ndububa DA, et al. Antibiotic resistance of Helicobacter pylori from patients in Ile-Ife, South-west, Nigeria. Afr Health Sci 2007; 7:.143-7.
Massarrat S, Sheykholeslami A. Increase in resistance rates of H. pylori isolates to metronidazole and tetracycline-comparison of three 3-year studies. Arch Iran Med 2010; 13: 177-87.
Kohanteb J, Bazargani A, Saberi-Firoozi M, Mobasser A. Antimicrobial susceptibility testing of Helicobacter pylori to selected agents by agar dilution method in Shiraz-Iran. Indian J Med Microbiol 2007; 25: 374-7.
Boyanova L, Davidkov L, Gergova G, Kandilarov N, Evstatiev I, Panteleeva E, et al. Helicobacter pylori susceptibility to fosfomycin, rifampin, and 5 usual antibiotics for H. pylori eradication. Diagn Microbiol Infect Dis 2014; 79: 358-61.
Kobayashi I, Murakami K, Kato M, Kato S, Azuma T, Takahashi Si, et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol 2007; 45: 4006-10.
Hu CT, Wu CC, Lin CY, Cheng CC, Su SC, Tseng YH, et al. Resistance rate to antibiotics of Helicobacter pylori isolates in eastern Taiwan. J Gastroenterol Hepatol 2007; 22: 720-3.
Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374-84.
Yue J-Y, Yue J, Wang M-Y, Song W-c, Gao X-Z. CagA status & genetic characterization of metronidazole resistant strains of H. pylori from a region at high risk of gastric cancer. Pak J Med Sci 2014; 30: 804–808.
- Abstract Viewed: 322 times
- PDF Downloaded: 172 times